Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations
This article was originally published in The Pink Sheet Daily
Executive Summary
The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.
You may also be interested in...
Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval
Alexion plans to use voucher for one of its own products and might be targeting its next-generation version of blockbuster Soliris.
Alexion’s Soliris REMS Gets FDA Panel Review In Wider Evaluation Effort
FDA advisory committee will revisit REMS for ultra-rare disease drug as part of larger agency effort to evaluate the effectiveness of the safety programs.
Alexion’s Costly Soliris For AHUS Raises “Cost Of Life” Issues At NICE
NICE is undeniably impressed with Alexion’s Soliris for treating aHUS but wants more data to justify its eye-watering price tag.